Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
Portfolio Pulse from
Protagonist Therapeutics announced positive results from Phase 3 studies of icotrokinra (JNJ-2113) for plaque psoriasis, achieving significant skin clearance. The company earned a $165 million milestone from its collaboration with Johnson & Johnson.
November 18, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's collaboration with Protagonist Therapeutics on icotrokinra achieved positive Phase 3 results, triggering a $165 million milestone payment.
The successful Phase 3 results for icotrokinra enhance J&J's portfolio in dermatology, potentially leading to future revenue streams and positively impacting its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Protagonist Therapeutics announced successful Phase 3 results for icotrokinra, leading to a $165 million milestone payment from Johnson & Johnson.
The positive Phase 3 results for icotrokinra, a key drug in Protagonist's pipeline, and the significant milestone payment from J&J are likely to boost investor confidence and positively impact PTGX's stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100